Diffuse large B-cell lymphoma trials in China

In China 133 Also abroad 346

133 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.

No phaseTaking people
Glofitamab in Chinese Patients With R/R DLBCL
Where
Beijing
Age
18 years to 80 years
People
20
Run by
Peking Union Medical College Hospital
See details and how to joinNCT06481826
Phase 3Taking people
Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP
Where
Changchun
Age
18 years to 80 years
People
200
Run by
Ou Bai, MD/PHD
See details and how to joinNCT07493109
Phase 2Taking people
Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL
Where
Changchun
Age
70 years and over
People
50
Run by
Ou Bai, MD/PHD
See details and how to joinNCT07493148
No phaseTaking people
A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL
Where
Beijing
Age
18 years and over
People
20
Run by
Peking Union Medical College Hospital
See details and how to joinNCT05514327
Phase 2Taking people
Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination.
Where
Beijing
Age
18 years to 85 years
People
30
Run by
Daihong Liu
See details and how to joinNCT07489989
No phaseNot yet taking people in China
Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma
Where
Zhengzhou
Age
18 years and over
People
20
Run by
Henan Cancer Hospital
See details and how to joinNCT07472621
Phase 2Taking people
Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)
Where
Guangzhou, Shanghai
Age
18 years to 80 years
People
42
Run by
Sun Yat-sen University
See details and how to joinNCT06517511
Phase 1/2Not yet taking people in China
Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study
Where
Guangzhou
Age
18 years to 70 years
People
122
Run by
Sun Yat-sen University
See details and how to joinNCT07398638
Phase 1/2Taking people
Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
Where
Beijing, Bengbu, Changchun, Dalian, Fuzhou, Guangzhou, Harbin, Jinan, Lanzhou, Liuzhou, Luzhou, Ma’anshan, Nanchang, Nanjing, Puyang, Quanzhou, Shanghai, Taiyuan, Tianjin, Wuhan, Xi’an, Xuzhou, Yantai, Zhengzhou
Age
18 years to 80 years
People
90
Run by
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
See details and how to joinNCT06829771
Phase 1Taking people
Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Where
Suzhou
Age
18 years and over
People
30
Run by
Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
See details and how to joinNCT07368270
Phase 2Taking people
Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma
Where
Beijing
Age
18 years and over
People
50
Run by
Beijing Tongren Hospital
See details and how to joinNCT07371923
Phase 3Enrolling by invitation
A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse Large B-cell Lymphoma
Where
Nanchang
Age
18 years to 75 years
People
80
Run by
Second Affiliated Hospital of Nanchang University
See details and how to joinNCT07348575
Phase 2Taking people
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
Where
Beijing, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Jilin City, Linyi, Luoyang, Meizhou, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Wuhan, Xiamen, Xuzhou, Zhengzhou
Age
18 years and over
People
150
Run by
Guangzhou Lupeng Pharmaceutical Company LTD.
See details and how to joinNCT07189065
Phase 2Taking people
Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
Where
Shanghai
Age
18 years to 75 years
People
152
Run by
Ruijin Hospital
See details and how to joinNCT06803693
Phase 2Taking people
Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL
Where
Suzhou
Age
18 years and over
People
29
Run by
The First Affiliated Hospital of Soochow University
See details and how to joinNCT07255963
Phase 2/3Taking people
Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma
Where
Guangzhou
Age
18 years and over
People
80
Run by
Sun Yat-sen University
See details and how to joinNCT07084662
Phase 2Not yet taking people in China
Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
Where
Guangzhou
Age
18 years and over
People
40
Run by
Li Zhiming
See details and how to joinNCT07231250
No phaseTaking people
Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma
Where
Fuzhou
Age
18 years to 75 years
People
20
Run by
Ting YANG
See details and how to joinNCT07188077
No phaseTaking people
Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relapsed and Refractory Diffuse Large B-Cell Lymphoma
Where
Fuzhou
Age
18 years to 75 years
People
10
Run by
Ting YANG
See details and how to joinNCT07198230
Phase 2Not yet taking people in China
Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS
Where
Nanjing
Age
18 years to 70 years
People
25
Run by
The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT06925555
Early phase 1Taking people
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research
Where
Hangzhou
Age
18 years and over
People
18
Run by
He Huang
See details and how to joinNCT06120166
Phase 3Taking people
A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma
Where
Chengdu
Age
18 years and over
People
390
Run by
Chengdu Zenitar Biomedical Technology Co., Ltd
See details and how to joinNCT07011056
Early phase 1Not yet taking people in China
Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma
Where
Xi'an
Age
18 years and over
People
3
Run by
First Affiliated Hospital Xi'an Jiaotong University
See details and how to joinNCT07168291
Phase 1/2Not yet taking people in China
Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Where
Hangzhou
Age
18 years to 99 years
People
62
Run by
First Affiliated Hospital of Zhejiang University
See details and how to joinNCT07159906
Phase 2Not yet taking people in China
A Phase 2 Study of TRS005 in Patients With CD20-positive R/R DLBCL.
Where
Beijing
Age
18 years and over
People
139
Run by
Zhejiang Teruisi Pharmaceutical Inc.
See details and how to joinNCT06886139